Search research articles
Contact Us
Filters
Showing results (81-90 of 162) with videos related to
Page
of 17
Sort By:
Journal of Clinical Pharmacology
|
May 15, 2013
Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus
Damayanthi Devineni, Christopher R Curtin, David Polidori, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 6, 2009
Incidence and evolution of oxaliplatin-induced peripheral sensory neuropathy in diabetic patients with colorectal cancer: a pooled analysis of three phase III studies
R K Ramanathan, M L Rothenberg, A de Gramont, et al.
Cancer Treatment and Research
|
January 1, 1989
Mechanisms of resistance to cisplatin and alkylating agents
T C Hamilton, G M Lai, M L Rothenberg, et al.
Cancer Chemotherapy and Biological Response Modifiers
|
January 1, 1994
New anticancer agents
G R Weiss, H A Burris, J R Eckardt, et al.
Journal of Substance Abuse Treatment
|
December 24, 2002
Behavioral naltrexone therapy: an integrated treatment for opiate dependence
Jami L Rothenberg, Maria A Sullivan, Sarah H Church, et al.
Blood
|
September 1, 1989
Expression of the mdr-1/P-170 gene in patients with acute lymphoblastic leukemia
M L Rothenberg, L A Mickley, D E Cole, et al.
American Journal of Clinical Oncology
|
October 8, 2008
A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignancies
Laura W Goff, Mace L Rothenberg, A Craig Lockhart, et al.
Clinical Pharmacology and Therapeutics
|
February 14, 2015
The role of nonrandomized trials in the evaluation of oncology drugs
R Simon, G M Blumenthal, M L Rothenberg, et al.
Biologics : Targets & Therapy
|
August 27, 2009
Analysis and variability of TGFbeta measurements in cancer patients with skeletal metastases
Peter J O'Brien, Rajeev Ramanathan, Jonathan M Yingling, et al.
Archives of General Psychiatry
|
February 8, 2006
Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial
Sandra D Comer, Maria A Sullivan, Elmer Yu, et al.
Page
of 17
Search research articles
Search
Showing results (81-90 of 162) with videos related to
Sort By:
Page
of 17
Journal of Clinical Pharmacology
|
May 15, 2013
Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus
Damayanthi Devineni, Christopher R Curtin, David Polidori, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 6, 2009
Incidence and evolution of oxaliplatin-induced peripheral sensory neuropathy in diabetic patients with colorectal cancer: a pooled analysis of three phase III studies
R K Ramanathan, M L Rothenberg, A de Gramont, et al.
Cancer Treatment and Research
|
January 1, 1989
Mechanisms of resistance to cisplatin and alkylating agents
T C Hamilton, G M Lai, M L Rothenberg, et al.
Cancer Chemotherapy and Biological Response Modifiers
|
January 1, 1994
New anticancer agents
G R Weiss, H A Burris, J R Eckardt, et al.
Journal of Substance Abuse Treatment
|
December 24, 2002
Behavioral naltrexone therapy: an integrated treatment for opiate dependence
Jami L Rothenberg, Maria A Sullivan, Sarah H Church, et al.
Blood
|
September 1, 1989
Expression of the mdr-1/P-170 gene in patients with acute lymphoblastic leukemia
M L Rothenberg, L A Mickley, D E Cole, et al.
American Journal of Clinical Oncology
|
October 8, 2008
A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignancies
Laura W Goff, Mace L Rothenberg, A Craig Lockhart, et al.
Clinical Pharmacology and Therapeutics
|
February 14, 2015
The role of nonrandomized trials in the evaluation of oncology drugs
R Simon, G M Blumenthal, M L Rothenberg, et al.
Biologics : Targets & Therapy
|
August 27, 2009
Analysis and variability of TGFbeta measurements in cancer patients with skeletal metastases
Peter J O'Brien, Rajeev Ramanathan, Jonathan M Yingling, et al.
Archives of General Psychiatry
|
February 8, 2006
Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial
Sandra D Comer, Maria A Sullivan, Elmer Yu, et al.
Page
of 17